...
首页> 外文期刊>Clinical nuclear medicine >Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol
【24h】

Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol

机译:与PET / CT相比,将整体式PET / MRI与18F-FDG,18F-FDOPA和18F-FDA结合用于神经节瘤中:NIH的单次注射,双模式成像方案的首次临床经验

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Paragangliomas (PGLs) are tumors that can metastasize and recur; therefore, lifelong imaging follow-up is required. Hybrid PET/CT is an essential tool to image PGLs. Novel hybrid PET/MRI scanners are currently being studied in clinical oncology. We studied the feasibility of simultaneous whole-body PET/MRI to evaluate patients with PGLs. METHODS: Fifty-three PGLs or PGL-related lesions from 8 patients were evaluated. All patients underwent a single-injection, dual-modality imaging protocol consisting of a PET/CT and a subsequent PET/MRI scan. Four patients were evaluated with 18F-FDG, 2 with F-fluorodihydroxyphenylalanine, and 2 with 18F-fluorodopamine. PET/MRI data were acquired using a hybrid whole-body 3-tesla integrated PET/MRI scanner. PET and MRI data (Dixon sequence for attenuation correction and T2-weighted sequences for anatomic allocation) were acquired simultaneously. Imaging workflow and imaging times were documented. PET/MRI and PET/CT data were visually assessed (blindly) in regards to image quality, lesion detection, and anatomic allocation and delineation of the PET findings. RESULTS: With hybrid PET/MRI, we obtained high-quality images in an acceptable acquisition time (median, 31 minutes; range, 25-40 minutes) with good patient compliance. A total of 53 lesions, located in the head and neck area (6 lesions), mediastinum (2 lesions), abdomen and pelvis (13 lesions), lungs (2 lesions), liver (4 lesions), and bones (26 lesions), were evaluated. Fifty-one lesions were detected with PET/MRI and confirmed by PET/CT. Two bone lesions (L4 body, 8 mm, and sacrum, 6 mm) were not detectable on an 18F-FDA scan PET/MRI, likely because 18F-FDA was washed out between PET/CT and PET/MRI acquisitions. Coregistered MRI tended to be superior to coregistered CT for head and neck, abdomen, pelvis, and liver lesions for anatomic allocation and delineation. CONCLUSIONS: Clinical PGL evaluation with hybrid PET/MRI is feasible with high-quality image and can be obtained in a reasonable time. It could be particularly beneficial for the pediatric population and for precise lesion definition in the head and neck, abdomen, pelvis, and liver.
机译:目的:副神经节瘤(PGLs)是可以转移和复发的肿瘤。因此,需要进行终身成像随访。混合PET / CT是对PGL成像的必不可少的工具。目前正在临床肿瘤学中研究新型混合PET / MRI扫描仪。我们研究了同时进行全身PET / MRI评估PGL患者的可行性。方法:对8例患者的53个PGL或与PGL相关的病变进行了评估。所有患者均接受单次注射,双模式成像方案,包括PET / CT和随后的PET / MRI扫描。评估了4例患者使用18F-FDG,2例使用F-氟二羟基苯丙氨酸和2例使用18F-氟多巴胺。使用混合式全身3特斯拉集成式PET / MRI扫描仪获取PET / MRI数据。同时获取PET和MRI数据(用于衰减校正的Dixon序列和用于解剖结构分配的T2加权序列)。记录了成像工作流程和成像时间。对PET / MRI和PET / CT数据进行视觉评估(盲法),包括图像质量,病变检测,解剖结构和PET发现的轮廓。结果:通过混合PET / MRI,我们在可接受的采集时间内(中值31分钟;范围25-40分钟)获得了高质量的图像,并且患者依从性良好。共有53个病变,位于头颈部区域(6个病变),纵隔(2个病变),腹部和骨盆(13个病变),肺(2个病变),肝脏(4个病变)和骨骼(26个病变) ,进行了评估。 PET / MRI检测到51个病变,PET / CT确认。在18F-FDA扫描PET / MRI上无法检测到两个骨病变(L4体,8毫米,骨,6毫米),这很可能是因为18F-FDA在PET / CT和PET / MRI采集之间被冲洗掉了。对于头部,颈部,腹部,骨盆和肝脏病变,就解剖学分配和轮廓而言,共同注册的MRI往往优于共同注册的CT。结论:混合PET / MRI的临床PGL评估具有高质量图像是可行的,并且可以在合理的时间内获得。这对于儿科人群以及头颈部,腹部,骨盆和肝脏的精确病变定义可能特别有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号